Archives
-
10 mM dNTP Mixture: PCR-Ready DNA Synthesis
2026-10-02
The 10 mM dNTP mixture is an equimolar aqueous stock containing dATP, dCTP, dGTP, and dTTP at 10 mM each. Its defined pH 7.0 formulation and storage recommendation at -20°C or below support standardized PCR, qPCR, sequencing, and other DNA synthesis workflows.
-
DiscoveryProbe FDA-approved Drug Library for LAG-3
2026-10-01
Explore how the DiscoveryProbe FDA-approved Drug Library supports mechanism-led LAG-3 research, from dual-ligand biochemical screening to cell-based validation. This article translates a landmark small-molecule study into practical decisions for drug repositioning screening and cancer research drug screening.
-
CP-673451: Selective PDGFRα/β Inhibitor
2026-10-01
CP-673451 combines nanomolar PDGFRα/β activity with a selectivity profile suited to pathway, angiogenesis, and tumor-model research. This practical guide explains how to build reproducible phosphorylation, cell-response, angiogenesis, and ATRX-stratified glioma workflows around the compound.
-
DiscoveryProbe FDA-approved Drug Library for AML
2026-09-30
Use the DiscoveryProbe FDA-approved Drug Library to move from broad compound screening to mechanism-led AML validation. Its pre-dissolved, clinically annotated collection supports efficient drug repositioning screening, high-content phenotyping, and target-focused follow-up without requiring de novo compound synthesis.
-
Gly-Gly-Phe-Gly (GGFG) Workflow Guide
2026-09-30
Gly-Gly-Phe-Gly is a compact, glycine-rich spacer for controlled drug conjugation research, peptide engineering, and biomaterial construction. This guide pairs practical GGFG handling and coupling workflows with assay-design lessons from a multiple-myeloma combination study, while clearly separating linker utility from disease-model evidence.
-
CDC42, NTCP, and HBV Entry: New Mechanistic Links
2026-09-29
The reference study identifies CDC42 as a regulator of hepatitis B virus entry through two connected but distinct mechanisms: Rab11-dependent delivery of NTCP to the plasma membrane and CDC42-dependent macropinocytosis. These findings refine the current model of HBV entry and suggest that host trafficking and actin-regulatory pathways may be relevant to antiviral research, while also defining important experimental controls for studying receptor localization and viral internalization.
-
Spiroplasma Entry into Drosophila S2 Cells
2026-09-29
Wei et al. established an invertebrate cell model showing that Spiroplasma eriocheiris enters Drosophila Schneider 2 cells through clathrin-mediated endocytosis and macropinocytosis, with additional dependence on actin filaments and microtubules. The study also separates these entry mechanisms from cholesterol-dependent caveola-like uptake and provides a practical inhibitor-based framework for investigating a poorly characterized crustacean pathogen.
-
Nicotinamide Riboside Chloride (NIAGEN) Research Guide
2026-09-28
Nicotinamide Riboside Chloride (NIAGEN) is a defined NAD+ precursor for studying cellular energy metabolism, sirtuin biology, and metabolic dysfunction. Evidence supports NAD-related biochemical activity and selected preclinical outcomes, but model-specific validation remains essential.
-
Cardamomin Limits Oxidative Injury in Stroke Models
2026-09-28
A study of cardamomin from Amomum villosum Lour. links antioxidant protection to MEK/ERK-associated NRF2 activation and reduced AIFM1-linked cell death in experimental models. Its combination of hydrogen peroxide-stressed BV-2 cells and permanent middle cerebral artery occlusion in rats provides mechanistic and tissue-level evidence, while leaving important questions about dosing, timing, and clinical relevance unresolved.
-
Localized BDNF Release in Early NMJ Assembly
2026-09-27
This study links muscle-derived BDNF trafficking and localized release to the earliest stages of postsynaptic acetylcholine receptor cluster formation at neuromuscular junctions. Its combination of cultured-cell perturbations and a muscle-specific knockout model supports a role for BDNF and furin-dependent processing, while leaving the contribution of extracellular MMPs unresolved.
-
Nilotinib (AMN-107) Kinase Research Workflows
2026-09-26
Build focused BCR-ABL experiments with practical dosing, phospho-readout, and troubleshooting guidance for Nilotinib (AMN-107). A separate p38α study offers a useful conformational-assay concept—but not evidence that nilotinib acts on p38α.
-
BCA Protein Quantification Kit K4102: Workflow Guide
2026-09-25
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 measures total protein in dilute samples, including cell lysates and many detergent-containing preparations. Use it for research measurement and sample normalization, not for diagnostic, clinical, or medical testing; check compatibility with the specific sample buffer before relying on results.
-
Streptavidin Magnetic Beads: K1301 Workflow
2026-09-25
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) capture biotinylated targets for magnetic recovery from complex samples, including protein, antibody, peptide, and nucleic-acid workflows. They are appropriate when the target or capture reagent is biotinylated; they are not a direct substitute for non-biotin affinity capture, and preservative and elution compatibility should be checked before cell-based or sensitive downstream assays.
-
Separating Growth Arrest from Cell Killing in Cancer
2026-09-24
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response: one combines growth inhibition and cell loss, while the other focuses on killing. The findings support time-aware, complementary measurements that can distinguish cytostatic from cytotoxic effects and sharpen interpretation of in vitro drug studies.
-
Nilotinib (AMN-107) Research Workflows
2026-09-24
Build reproducible Nilotinib workflows around target engagement—not viability alone—with practical guidance for BCR-ABL, KIT, and exploratory neuronal assays. A 2024 SH-SY5Y study also illustrates why protein-level checks and clear limits on cross-domain interpretation matter.